Conference Coverage (AACR)

Antiviral Activity of ISIS 5320 Oligonucleotide Tested In Vivo

Published in AIDS Weekly, June 9th, 1997

Results of toxicity and pharmacokinetic studies of the antiviral phosphorothioate oligonucleotide ISIS 5320 conducted in cynomolgus monkeys were presented at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California.

"ISIS 5320 is a phosphorothioate oligonucleotide which binds to the V3 loop of the viral envelope protein gp120, preventing fusion of HIV to the cellular CD4 receptor," explained researcher Karen Schwikart, of the U.S. National Cancer Institute, Bethesda, Maryland at the conference. "It is active against HIV-1 and HIV-2 isolates, including clinical strains."

Schwikart's group conducted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-06-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry